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Mitochondrial diseaseCoenzyme Q is an isoprenylated benzoquinone lipid that functions in respiratory electron transport and as a
lipid antioxidant. Dietary supplementation with Q is increasingly used as a therapeutic for treatment of
mitochondrial and neurodegenerative diseases, yet little is known regarding the mechanism of its uptake. As
opposed to other yeast backgrounds, EG103 strains are unable to import exogenous Q6 to the mitochondria.
Furthermore, the distribution of exogenous Q6 among endomembranes suggests an impairment of the
membrane trafﬁc at the level of the endocytic pathway. This fact was conﬁrmed after the detection of defects
in the incorporation of FM4-64 marker and CPY delivery to the vacuole. A similar effect was demonstrated in
double mutant strains in Q6 synthesis and several steps of endocytic process; those cells are unable to uptake
exogenous Q6 to the mitochondria and restore the growth on non-fermentable carbon sources. Additional
data about the positive effect of peptone presence for exogenous Q6 uptake support the hypothesis that Q6 is
transported to mitochondria through an endocytic-based system.© 2009 Elsevier B.V. All rights reserved.1. IntroductionCoenzyme Q (ubiquinone or Q) serves as a redox active lipid in the
respiratory chain of prokaryotes and eukaryotes [1,2], and there is an
increasing appreciation of its use in therapeutic, nutritional and
cosmetic applications. Coenzyme Q10 (the subscript designates the
number of isoprene units in the polyisoprene tail) has been used
successfully to aid patient recovery following ischemia post reperfu-
sion in heart transplantation [3] and cardiac surgery [4], and also
shows promise as a therapeutic agent in other cardiovascular diseases
including atherosclerosis [5], and chronic heart failure [6].
Dietary supplementation with Q10 helps slow the progression of
symptoms in patients with Parkinsons disease [7,8], and may have
similar beneﬁts in Alzheimer [9] and Huntington diseases [10]. There
is intense interest in mitochondrial diseases based on their apparent
relationship with neurodegenerative diseases. A subset of mitochon-
drial diseases associated with decreased levels of Q10 such asid-enriched complexes; CPY,
icrosomes; Q, coenzyme Q or
SNARE, soluble N-ethylmalei-
trans-Golgi network; t-SNARE,
a del Desarrollo, Universidad
a, Spain. Tel.:+34 954 349093;
ll rights reserved.cerebellar ataxia [11,12] Q-deﬁcient mitochondrial diseases [13,14]
can be alleviated by Q10 administration. Dietary supplementationwith
Q has been proposed to extend lifespan of rats fed diets enriched with
polyunsaturated fatty acids [15]. Several studies demonstrate a decline
in Q content during ageing [16], however dietary supplementation
with Q10 did not affect life span of mice fed standard chow diets [17].
There are also studies that indicate a decrease in Q biosynthesis may
actually extend lifespan of nematodes and mice [18]. Thus, there is a
complex relationship between the beneﬁcial functions of Q (as an
antioxidant and in energy metabolism) and its potential to act as a
source of oxidative stress (with the protein complexes of the
respiratory electron transport chain).
The efﬁcacy of Q supplementation is determined by its bioavail-
ability to tissues and cells. Studiesmeasuringuptake of Q10 have shown
an extremely diverse distribution [19]. Despite the prevalent use of Q10
as a dietary supplement, little is known about the mechanisms
responsible for its uptake. It is possible that both cellular uptake of
exogenously supplied Q and intracellular transport of endogenously
synthesized Q share a commonpathway. Studies in human cells by cell
fractionation indicate that Q10 is synthesized within the mitochondria
and distributed to other cell membranes via the endomembrane
system [20]. This system also participates in the uptake of exogenous
Q10 suggesting that the endo-exocytic pathways play a role in
distributing Q amongmembranes. In eukaryotes, Q is not only present
in mitochondria, but is also located in a wide variety of cellular
membranes and organelles, including the Golgi and endoplasmic
Table 1
Genotype and sources of S. cerevisiae strains used in this work.
Strain Genotype Source
EG103 α his3Δ1, leu2–3,112 trp1–289, ura3–52, gal2 [62]
EG103 coq7 EG103Δcat5::HIS3 [50]
EG103 coq3 EG103Δcoq3::LEU2 This study
CEN.PK2-1C A, his3-Δ1, leu2–3,112, trp1–289, ura3–52,
MAL2–8c, MAL3, SUC3
[63]
CEN coq7 CEN PK2-1C Δcat5::HIS3 [63]
CEN coq3 CEN PK2-1C Δcoq3::LEU2 This study
BY4741 A, his3Δ1, leu2Δ0,met15Δ0, ura3Δ0 Euroscarf
BY4741 coq3 BY4741Δcoq3::LEU2 This study
Y01709 (tlg2) BY4741 YOL018c::KanMX4 Euroscarf
Y01709 coq3 Y01709Δcoq3::LEU2 This study
Y04462 (vps45) BY4741 YGL095c::KanMX4 Euroscarf
Y04462 coq3 Y04462Δcoq3::LEU2 This study
Y00788 (pep12) BY4741 YMR202w::KanMX4 Euroscarf
Y00788 coq3 Y00788Δcoq3::LEU2 This study
Y01812 (erg2) BY4741 YOR036w::KanMX4 Euroscarf
Y01812 coq3 Y01812Δcoq3::LEU2 This study
NY431 MAT a ura3–52 sec18-1 [64]
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that it may perform other functions. The reduced form of coenzyme Q,
ubiquinol (QH2), acts as an antioxidant and may prevent lipid
peroxidation in membranes [22,23]. QH2 acts directly to scavenge
lipid peroxyl radicals and also acts as a co-antioxidant to quench α-
tocopheryl radicals and regenerateα-tocopherol [24,25]. In addition, Q
functions in the plasma membrane redox system in Saccharomyces
cerevisiae [26] and mammalian cells [27,28], and may also participate
in the electron transport chain of lysosomal membranes [29].
Despite the widespread distribution of Q, the biosynthesis of
this molecule appears to be restricted. Studies in mammalian cellsFig. 1. Assessment of purity of yeast membrane fractions from the CEN.PK2-1C strain. In Supp
The extent of cross-contamination in endomembrane samples (30 μg of protein) was determ
DIGs were puriﬁed by an Optiprep gradient (seeMaterials andmethods). Fraction 2 of the ﬁrs
gradient. Fraction 2 from the second gradient was considered as the pure DIGs fraction. Pm
Vacuole and Golgi membrane fractions were puriﬁed from a sorbitol step gradient. Fractions
and Vps10p for Golgi.suggested that Q was synthesized in mitochondria, Golgi apparatus
and endoplasmic reticulum [21], and it was proposed that the high
level of Q synthesis in Golgi apparatus serves as a reservoir for its
subsequent distribution among cell membranes. However, more
recent studies in yeast, nematodes, and mammals indicate that the
enzymes of Q biosynthesis are located in the matrix side of the
inner mitochondrial membrane. In the yeast Saccharomyces cerevi-
siae the sub-mitochondrial localization of each of the Coq1p–Coq9p
polypeptides was determined by subcellular fractionation and
mitochondrial in vitro import experiments [30]. Furthermore,
human, nematode and rat gene homologues rescue the Q
biosynthetic defects of the coq3, coq5 and coq7 yeast mutants
[31–35]. Recent studies have demonstrated that homologues of
yeast Coq7p in Caenorhabditis elegans and mouse are located in
mitochondria [36–38]. Further, human Coq4 is also located in
mitochondria [39].
Results described above indicate that Q biosynthesis occurs within
mitochondria, at least in yeast but the fact that Q is located in every
cell membrane component suggests the existence of a mechanism for
its distribution. Lipid transport, including phospholipids, has been
extensively studied in Saccharomyces cerevisiae [40,41], however, very
little is known about the transport of Q. Some evidence for
mobilization of Q is indicated by studies with the HL-60 cell line.
HL-60 cells that have lost mitochondrial DNA by ethidium bromide
treatment or have been grown in a serum-deprived media contain
increased amounts of Q at the plasma membrane [42]. This
observation suggests a speciﬁc Q transport mechanism that may
regulate its distribution among cell membranes in response to stress
or metabolic demands.
In this study, we have tested the role of the membrane trafﬁc
pathway in cellular uptake of exogenous Q. In the ﬁrst approach welementary material was shown the corresponding analysis for the EG103 strain. Panel A:
ined by SDS-PAGE andWestern blot with speciﬁc antibodies to marker proteins. Panel B:
t gradient (enriched in both Pma1p and Gas1pmarker proteins) was applied to a second
a1p and Gas1p are considered as speciﬁc marker proteins of DIGs membranes. Panel C:
most enriched with vacuole and Golgi marker proteins were identiﬁed; ALP for vacuole,
Fig. 2. Coenzyme Q6 content in yeast membrane fractions. Lipid extracts were obtained
from puriﬁed membrane fractions and the content of Q6 was determined with HPLC-
ECD as described in Materials and methods. Results shown are the average of three
injections±SD of two independent extractions. Panel A: CEN.PK2-1C (wt) and CENcoq7
strains cultured in absence or presence of 2 μM. Panel B: EG103 (wt) and EG103 coq7
strains cultured in absence or presence of 2 μM Q6. All cells were cultured in YPD. The
asterisk (⁎) indicates that Q6 was not detected.
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EG103 and CEN.PK2-1C. In Q6 deﬁcient mutants of both backgrounds
was determined the distribution of Q6 after it exogenous supplemen-
tation. While EG103 is known to have defects in the import of
exogenous Q6 to the mitochondria, CEN.PK2-1C is competent for such
import. This behavior was associated with defects in typical trafﬁc
membrane markers. Therefore, in the second approach we analyzed
the distribution of exogenous Q6 in endocytic-deﬁcient strains with
defects in Q6 biosynthesis. Both approaches delineate a general map of
Q6 transport that explains the bioavailability of exogenous Q in
eukaryotic cells.
2. Materials and methods
2.1. Yeast strains and growth media
The yeast strains used in this study are described in Table 1.
Yeast were grown in rich YPD medium (1% yeast extract, 2%
peptone, and 2% dextrose) and in YPG (1% yeast extract, 2% peptone,
and 3% glycerol). Deﬁned media contained 0.18% yeast nitrogen base
without amino acids, 2% dextrose, 0.14% NaH2PO4, 0.5% (NH4)2SO4,
and either a complete amino acid supplement (SDc) or without
uracil (SDc-ura). Yeast liquid cultures were grown at 30 °C with
shaking at 200 rpm.
2.2. In situ disruption of the coq3 gene in yeast mutants harboring
defects in endocytic pathways
A coq3::LEU2 disruption cassette was obtained from the plasmid
pCleu12 [43]. In this plasmid a 0.7-kb BglII DNA segment of the yeast
COQ3 coding region has been replaced with a 2.85-kb BglII fragment
of YEp13 containing the LEU2 gene. Digestion of pCleu12 with PstI and
BamHI generates a linear fragment of 4.65-kb that was used to disrupt
the COQ3 gene in each of the designated mutants of the endocytic
pathway. All strains were transformed with 1 μg of the PstI/BamHI
linear fragment frompCleu12 by the lithiumacetate/PEGmethod [44].
In the strain NY431 (sec18-1) the coq3 disruption required a coq3::
URA3 cassette. The URA3 gene cassette was obtained by PCR from the
plasmid pRS316 using speciﬁc primers containing ﬂanking sequences
complementary with the gene COQ3 (COQ3-URA3-F 5′-AAC GAG ATG
TAAGAG CACAGATGCGGAATAAGGGCGACAC-3′ and COQ3-URA3-R
5′-AAGAGTATACCTTTT TCGGGATTTGACAGCTTATCATCGA-3′). The
ampliconwas puriﬁed from the agarose gel and used to transforms the
NY431 strain by the lithium acetate/PEG method [44].
The presence of the coq3 gene deletion in the different yeast
strains was ascertained by HPLC-ECD detection of Q6 (Figure S2, Panel
A) and by PCRwith speciﬁc primers that amplify a COQ3DNA segment
internal to the fragment excised by BglII digestion (Figure S2, Panel B).
Primers and experimental conditions were designed with Primer
Premier 5 software (Premier Biosoft International, USA). PCR was
performed with Touch-Down PCR (annealing temperature 62 °C to
50 °C at 0.5 °C/cycle) with the sense primer coq3U96 (5′-
AACGAGATGTAAGAGCACAGATGC-3′) and the antisense primer
coq3L660 (5′-AAGAGTATACCTTTTTCGGGATTT-3′). Because this is a
negative test, each PCR reaction contained a second set of primers
amplifying an internal sequence of the gene ACT1 (ACT1F 5′-
TTCTGAGGTTGCTGCTTTGG-3′ and ACT1R 5′-GATCCACATTTGTTG-
GAAGGTGGTAGTC-3′). ACT1 primers were designed to avoid non-
desired interactions with COQ3 primers and ﬁrst were tested in a
separate reaction.
2.3. Puriﬁcation of yeast subcellular fractions
Yeast plasma membranes were puriﬁed as described with some
modiﬁcations [45]. Yeast cells were lysed by vortexing with glass
beads and centrifuged (10 min at 700 ×g) to remove debris. Thesupernatant was centrifuged (30 min at 20,000 ×g) to obtain a crude
membrane pellet. Crude membranes were resuspended in sucrose
buffer (20% w/w sucrose, 10 mM Tris–HCl, pH 7.6, 1 mM EDTA and
1mMdithiothreitol) and applied to a sucrose step gradient comprised
of 4 ml 43% (w/w) sucrose and 2 ml 53% (w/w) sucrose in the same
buffer. After centrifugation (4 h at 100,000 ×g), plasma membranes
were recovered at the 43/53 interface and reapplied to a second
sucrose step gradient as before. To remove non-intrinsic plasma
membrane proteins, the samples were treated with 100 mM Na2CO3,
pH 11.5 [46], and suspended in the same buffer with 0.33 M sucrose.
Detergent-insoluble glycolipid-enriched complexes (DIGs) were
isolated as described previously [47]. Cells (10–20 OD660 units) were
broken with glass beads in TNE buffer (50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 5 mM EDTA) and centrifuged (10 min at 700 ×g) to
remove debris. The cleared lysate (1.5 ml) was incubated with TX100
(1% ﬁnal concentration) for 30 min on ice. After the extraction with
TX100, the lysate was adjusted to 40% Optiprep (Sigma, Spain) by
adding 3 ml 60% Optiprep solution and overlaid with 7.2 ml of 30%
Optiprep in TXNE (TNE, 0.1% TX100) and 1.2 ml of TXNE. The samples
were subjected to centrifugation (140,000 ×g, 10 h), and six fractions
of 1.4 ml were collected from the top. The second fraction was
subjected to a second incubation with TX100 and reapplied to a
second Optiprep (Sigma, Spain) gradient as before to obtain a fraction
of puriﬁed DIG's by collecting the second 1.4 ml fraction from the top.
Other membrane fractions required the preparation of yeast
spheroplasts, obtained by treatment with zymolyase in buffer B
(1.2 M sorbitol, 20 mM potassium phosphate, pH 7.4) [48].
Spheroplasts were resuspended with C buffer (0.6 M manitol,
20 mM potassium phosphate, pH 7.4), lysed with a Dounce
homogenizer and centrifuged (10 min at 700 ×g) to remove debris.
The supernatant was centrifuged 10 min at 12,000 ×g to obtain a
pellet of crude mitochondria. The resulting supernatant was
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fraction. The supernatant was centrifuged 45 min at 32,500 ×g to
obtain rough endoplasmic reticulumpellet, and then 1 h at 100,000 ×g
to obtain smooth endoplasmic reticulum pellet. Crude mitochondria
were applied to aNycodenz step gradient of 4.5ml 14.5%Nycodenz and
4.5 ml 20% Nycodenz in C buffer. After centrifugation (1 h at
100,000 ×g), mitochondriawere recovered from the 14.5/20 interface.
The upper fraction of the Nycodenz gradient was used to purify MAM
(mitochondria associated microsomes); this fraction was applied to a
sucrose step gradient of 5 ml 50% sucrose and 5 ml 22.5% sucrose in C
buffer. After centrifugation (1 h at 100,000 ×g), the MAM fractionwas
recovered from the top of the gradient.
Vacuole and Golgi apparatus fractions were puriﬁed as described
by Wu et al. [49]. Spheroplasts were obtained as above, resuspended
in 0.6 M Sorbitol, 20 mM K+-MES, pH 6.0 and lysed with a Dounce
homogenizer. After cell lysis, the homogenate was centrifuged ﬁrst at
700 ×g to remove debris and 12,000 ×g to remove an enriched
mitochondria fraction. The supernatant was centrifuged 30 min at
30,000 ×g and the pellet obtained was suspended in the same buffer
and applied to a sorbitol step gradient of 5 ml 80% (w/v) sorbitol and
5 ml 25% (w/v) sorbitol in 10 mM triethanolamine, pH 7.4. The
interface between the 25 and 80% sorbitol layers was collected andFig. 3. Analysis of trafﬁc membrane markers in CEN.PK2-1C and EG103 cells. Panel A: CPY
undiluted, 1:10, 1:100 or 1:1000 dilutions (left to right) on a nitrocellulose ﬁlter overlaid on
Materials and methods. Extracellular CPY secreted from colonies was detected by inmunos
Yeast cell grown to logarithmic phase in YPD were incubated with 2 μM FM4-64at 30 °C d
ﬂuorescence microscope. Micrographs are obtained with 1000× magniﬁcation. Bar, 5 μm. Radjusted to 43% sorbitol and layered on a gradient prepared in 40, 43,
60, 70 and 80% increments of 2.3 ml each. Following centrifugation
(120,000 ×g, 48 h), fractions were collected from the top (0.6 ml) and
monitored by immunoblot with antibodies that recognized vacuole
and Golgi apparatus speciﬁc proteins.
To check the purity of membrane fractions, SDS-PAGE andWestern
blotting were performed using standard methods (Fig. 1). Primary
antibodies that recognized speciﬁc proteins of membrane fractions
were used at the following dilutions: 1:50,000 Pma1p (plasma
membrane); 1:20,000 Gas1p (DIGs); 1:5000 porin (mitochondria
outer membrane); 1:10,000 cytochrome c1 (mitochondria inner
membrane); 1:10,000 Sec62p (endoplasmic reticulum); 4 μg/ml
Vps10p (Golgi) and 2 μg/ml Alkaline phosphatase (vacuole) from
Molecular Probes. Horseradish peroxidase-linked secondary antibo-
dies to rabbit and mouse IgG were used in 1:10,000 (rabbit) and
1:5000 (mouse) dilutions.
2.4. Lipid extraction and determination of Q6
Lipid extractions and quantiﬁcation of Q6 from puriﬁed membrane
samples were performed as described previously [50]. Aliquots of
puriﬁedmembrane fractions (500 μl, 0.5–1mg of protein) weremixedsecretion. Equal number of cells from freshly grown yeast cultures were deposited as
YPD plates. The plates were incubated for 24 h at 30 °C and washed as described under
taining with anti-CPY antibody (Molecular Probes). Panel B: FM4-64vacuolar staining.
uring 30 min. After incubation, cells were washed with PBS and observed under the
esults are representative of a set of three experiments.
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isopropyl alcohol in ethanol was added, and samples were vortexed
again for 1 min. To recover quinones, 5 ml of hexane were added, and
the mixture was vortexed at top speed for 1 min and centrifuged at
1000 ×g for 5 min. The upper phases recovered from three extractions
were pooled and dried in a rotatory evaporator. Lipid extracts were
suspended in 1 ml of ethanol dried in a speed-vac and kept at−20 °C.
Samples were suspended in a suitable volume of ethanol prior to HPLC
injection. Q6 and Q9 were separated by reverse-phase high perfor-
mance liquid chromatography with a C18 column and quantiﬁed with
an ESA Coulochem III electrochemical detector and a 5010 analytical
cell (E1, −500 mV; E2, +500 mV). A separate precolumn guard cell
was set to an oxidizing mode (E, +500 mV) to convert all
hydroquinones to quinones. The mobile phase was adjusted to a
ﬂow rate of 1 ml/min and was composed of methanol/ethanol/2-Fig. 4. Analysis of trafﬁc membrane markers. Panel A: CPY secretion in single membrane tra
undiluted, 1:10, 1:100 or 1:1000 dilutions (left to right) on a nitrocellulose ﬁlter overlaid on
Materials and methods. Extracellular CPY secreted from colonies was detected by inmunos
Yeast cell grown to logarithmic phase in YPD were incubated with 2 μM FM4-64at 30 °C
ﬂuorescencemicroscope. Results are representative of a set of three experiments. Micrograph
membrane trafﬁc/coenzyme Q biosynthesis double mutants. Yeast cell grown to logarithmic
cells were washed with PBS and observed under the ﬂuorescence microscope. Results are
magniﬁcation. Bar, 5 μm.propanol (88/24/10) and 13.4 mM lithium perchlorate. Q6 and Q9
were quantiﬁed from the electrochemical detector results with Q6 and
Q9 as external standards. The use of Q9 as an internal standard (10 μl of
a 2 mM stock) indicated a recovery of 90–100% of total Q9 added to
samples.
2.5. CPY secretion plate assay
Yeast cultures were freshly grown to logarithmic phase and
washed with deionized water. 50×106 yeast cells were resuspended
in 1 ml of sterile water and three ten fold dilutions were made. All
dilutions were spotted on a nitrocellulose membrane which was
placed on the surface of YPD plates and incubated at 30 °C for 24 h. The
membranes were lifted and washed with deionized water to remove
all the cells. Proteins adsorbed on the membrane were detected byfﬁc mutants. Equal number of cells from freshly grown yeast cultures were deposited as
YPD plates. The plates were incubated for 24 h at 30 °C and washed as described under
taining with anti-CPY antibody (Molecular Probes). Panel B: FM4-64vacuolar staining.
during 30 min. After incubation, cells were washed with PBS and observed under the
s are obtainedwith 1000×magniﬁcation. Bar, 5 μm. Panel C: FM4-64vacuolar staining in
phase in YPDwere incubatedwith 2 μMFM4-64 at 30 °C during 30min. After incubation,
representative of a set of three experiments. Micrographs are obtained with 1000×
Fig. 5. Exogenous Q6 fails to rescue yeast coq3 mutants containing additional deletions
in genes required for endocytosis. Panel A: YPGmediawith 2 μMQ6was inoculatedwith
0.1 OD660nm units/ml of the designated yeast strains and incubated at 30 °C with
shaking. Data correspond to the average±SD of ﬁve measures of the same culture.
Experiment is representative of a set of two independent experiments. Panel B: Yeast
strains bearing defects in membrane trafﬁcking are able to grow in non-fermentable
carbon source. Equal number of cells from freshly grown yeast cultures were deposited
as undiluted, 1:10, 1:100 or 1:1000 dilutions (left to right) on YPD and YPG plates. The
plates were incubated for 48 h at 30 °C.
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1:5000 dilution).
2.6. Vacuolar staining with FM4–64
Yeast cells were grown in YPD media to logarithmic phase.
Aliquotes of 1 ml were harvested by centrifugation and washed
twice with 1 ml of PBS. Then, cells were resuspended in 1 ml of PBS
and incubated with 2 μM FM4-64at 30 °C for 30 min. After incubation,
yeast cells were washed twice with PBS, resuspended again in fresh
PBS and observed under the ﬂuorescence microscope (λexc=515 nm,
λem=640 nm).
3. Results
3.1. Exogenous coenzyme Q6 is differentially distributed among cell
membranes in CEN.PK2-1C and EG103 yeast
In order to delineate the inﬂuence of yeast genetic background on
the distribution of Q6 among yeast cellular membranes, the Q6 content
was analyzed in membranes of wild-type and coqmutant yeast strains
derived from the CEN.PK2-1C and EG103 genetic backgrounds. Wild-
type strains were grown in rich medium containing glucose as a
fermentable carbon source (YPD). Null coq7mutants were cultured in
the same media supplemented with 2 μM exogenous Q6. All coq
mutants are unable to synthesize Q6 and the Q6 detected come from
the exogenous supplementation The content of Q6 was determined in
several membrane fractions including mitochondria, mitochondria-
associated microsomes (MAM), smooth and rough endoplasmic
reticulum (SER and RER), Golgi apparatus, vacuole, plasmamembrane
and detergent-insoluble glycolipid-enriched complexes (DIGs) (Fig. 1
and S1). The subcellular fractionation was not signiﬁcantly affected in
the different mutants analyzed. Lipid extracts were prepared from
each membrane fraction, and the content of Q6 was determined by
HPLC-ECD (Fig. 2, Panels A and B). In wild-type cells (black bars) Q6
content was highest in wild-type mitochondria and vacuole, being
lowest in DIGs, smooth ER and plasma membrane. The MAM fraction
of CEN.PK2-1C yeast was dramatically enriched in Q6 (Fig. 2, Panel A),
but this enrichment was not evident in the EG103 yeast.
Addition of exogenous Q6 restores respiration in the coq7 null
mutant derived from CEN.PK2-1C but not EG103 yeast parental strains
[50]. Thus it was of interest to compare the relative amounts of
exogenously added Q6 contained in membrane fractions prepared
from these coq7mutants. The presence of exogenously added Q6 led to
dramatic differences in the distribution of Q6 among membrane
fractions, as evidenced by the much higher Q6 content in mitochon-
dria, MAM and RER in the coq7 mutant derived from CEN.PK2-1C as
compared to EG103 (Fig. 2, Panels A and B, white bars). The level of Q6
in EG103coq7 mitochondria was only 22% of wild-type, while the Q6
content of the CEN coq7 mutant was 75% of wild-type. Q6 levels in
wild-type strains are not affected signiﬁcantly after the exogenous Q6
supplementation.
3.2. Two phenotypes associated to membrane transport defects are
present in EG103 genetic background
Q6 distribution in coq7 null mutant from EG103 genetic back-
ground suggests that membrane trafﬁc might be involved in the
uptake and transport of this lipid to the mitochondria. With the above
in mind, we decided to further investigate a potential membrane
trafﬁcking defect in EG103 yeast cells.
Carboxypeptidase Y (CPY) is synthesized as a prepro form and is
transported across the endoplasmic reticulum membrane. Following
signal peptidase cleavage in the ER to produce a 67 kDa precursor (p1)
form, it is transported through the Golgi where it acquires sugar
modiﬁcations to become a 69 kDa (p2) form. Wild-type cells are ableto correctly deliver CPY to its ﬁnal destination within the vacuolar
lumen, where it is processed to a 61 kDa mature form. However, yeast
mutants with defects in protein/membrane trafﬁcking to the vacuole
secrete a portion of the p2 form of CPY [51]. To investigate whether
EG103 cells present this phenotype, a plate assay was performed as
described in Materials and methods. We did no detect any CPY
secretion associated to the parental and coq7 null mutant strains
derived from CEN.PK2-1C genetic background. Interestingly, a mild
CPY secretion was detected in yeast strains from EG103 (Fig. 3, Panel
A), indicating a potential membrane trafﬁcking defect associated to
this genetic background.
It should be noted that whereas yeast mutants with defects in
membrane trafﬁc to the vacuole secrete CPY, there are many others
mutants that secrete low levels of this protein [52]. However, it is well
known that defects in trafﬁcking to the vacuole lead to alterations of
the vacuolar morphology [53]. Therefore, to further conﬁrm the above
results, we decided to analyze the vacuolar morphology of the yeast
cells in both genetic backgrounds studied performing FM4-64staining.
Yeast cells grown to logarithmic phase in YPD media were harvested
and incubated with the dye as described in Materials and methods.
The results (Fig. 3, Panel B) evidenced that either parental or coq7 null
cells from CEN.PK2-1C have generally one well deﬁned vacuolar
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yeast cells from EG103 background, which supports above CPY
secretion results and strongly suggests an altered membrane trafﬁck-
ing pathway in EG103 cells.
The above results support the hypothesis that altered Q6 distribu-
tion among cell membranes observed in EG103 cells may be a
consequence of a partial impairment in the normal membrane
trafﬁcking processes that occur within the cell.
3.3. The endocytic pathway is involved in Q6 uptake in yeast
To conﬁrm whether either an impaired endocytosis or a defective
membrane trafﬁc lead to an alteration of coenzyme Q uptake and its
transport to the mitochondria, we analyzed the uptake and
distribution of exogenous Q6 in mutant strains with gene defects
in several endocytic transport steps such as ERG2, PEP12, TLG2 or
VPS45 genes. Erg2p catalyzes a step in ergosterol biosynthesis and
this deﬁciency induces the accumulation of sterol intermediates that
support growth and exocytosis but fail to allow endocytic transport
[54]. Pep12p is a syntaxin controlling the vesicular trafﬁc in the
prevacuolar compartment [55]. Tlg2p is a t-SNARE (target soluble
N-ethyl maleimide-sensitive factor attachment protein receptor)
protein required for the fusion of trans-Golgi network vesicles (TGN
vesicles) with endocytic vesicles to produce early endosomes [56].
Vps45p is a SM protein (Sec1p-like/Munc-18) required for Tlg2p
function [57]. These single mutant yeast strains (in the BY4741
genetic background) were obtained from the Euroscarf repository,
and each retained the ability to grow on media containing glycerol
as a non-fermentable carbon source (Fig. 5, Panel B). MembraneFig. 6. Coenzyme Q6 content in endomembranes of coq3/endocytic double mutants. Lipid ex
puriﬁed from parental (wt), coq3 single mutant, and coq3/endocytic double mutants culture
expressed as the average±SD of three injections. Data are representative of two independetrafﬁc impairment in those mutants was conﬁrmed by analyzing
CPY secretion (Fig. 4, Panel A) and performing a vacuolar staining
with FM4-64 (Fig. 4, Panel B). As expected, all the mutant strains
showed a high level of CPY secretion and different kind of
alterations in the vacuolar morphology. Using these strains and
the parental BY4741 strain, mutant strains unable to synthesize Q6
were obtained by in situ gene disruption of the COQ3 gene. Null
coq3 mutants show the same behavior as null coq7 mutants in
terms of having defects in Q6 biosynthesis, inability to grow on non-
fermentable carbon sources, and defects in respiration. Each of the
double mutants was shown to have a defect in producing Q6 (Figure
S2, Panel A) and to lack the wild-type COQ3 gene (Fig. 5, Panel B).
The transformation of double mutants with the plasmid pRS12A-
2.5SB (containing the COQ3 gene) restores the growth on YPG
plates (Figure S2, Panel C). Moreover, the additional COQ3 deletion
in double mutant strains did not alter either CPY secretion or FM4-
64staining phenotypes observed in BY4741 parental and mutant
strains (Fig. 4, Panel C).
To test exogenous Q6 uptake, each double mutant yeast strain was
cultured in YPG medium supplemented with 2 μM Q6. None of the
double mutants were able to grow in this medium (Fig. 5). However,
the coq3 single mutant prepared in the BY4741 genetic background
showed growth rescue in YPGmedium supplemented with Q6 (Fig. 6).
These results suggest that endocytosis and membrane trafﬁcking are
required for Q6 to reach mitochondria in these cells.
To determine whether the exogenously supplied Q6 was able to
reach endomembranes, the Q6 content was determined in puriﬁed
fractions of plasma membrane, Golgi apparatus, vacuole and mito-
chondria from the parental, the coq3 single mutant, and each of thetracts were obtained frommitochondria, plasma membrane, Golgi and vacuole fractions
d in YPD with 2 μM Q6. The content of Q6 was determined by HPLC-ECD and results are
nt experiments.
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(Fig. 7, Panel A). The content of Q6 in plasma membrane of wild-
type and coq3 mutant strains contained a similar amount of Q6,
while Golgi, mitochondria, and vacuoles isolated from the coq3
mutant contained 59%, 57% and 32% of the wild-type Q6 content.
However, each of the coq3-double mutant strains lacking endocy-
tosis related genes showed dramatically decreased Q6 content in all
membrane fractions analyzed. The low Q6 content in plasma
membranes of the coq3-double mutants is particularly intriguing,
as it suggests that most of the exogenously supplied Q6 cannot be
directly incorporated into the plasma membrane. A direct insertion
of Q6 into the plasma membrane seems to be difﬁcult due the
extremely low solubility in water. Given that another lipids such as
sterols are transported to the cell using protein–lipid complexes
through the endocytic pathway [41], we analyzed the possibility
that peptone plays the function of a vehicle for exogenous Q6.
However, the use of constitutive deleted mutants could introduce
in the analysis already affected transport pathways or putative
transporters. To solve this question, has been analyzed the Q6
exogenous transport in a double mutant NY431 coq3 (sec18-1/coq3)
under non-permissive temperature (Fig. 7, Panel B). Sec18p is an AAA-
ATPase, the orthologue of NSF in mammalian cells. In the yeast
expressing the sec18-1 mutant protein, the transport ceases after
shifting the cells to the non-permissive growth temperature [58].
NY431 coq3 is unable to synthesize Q6 given that harbors the coq3
mutation. Before the addition of exogenous Q6, this molecule is notFig. 7. Coenzyme Q6 uptake is favored by the presence of peptone in culturemedia and is affec
from several Q-deﬁcient strains (CEN coq3, EG103 coq3 and coq3/erg2) were cultured in SD
without 2% peptone. Cells were cultured for 48 h, harvested, and the cell wall removed by
described in Materials and methods. Data correspond to the average±SD of three Q6 determ
experiments. aThe addition of peptone increase signiﬁcantly the levels of Q6 (pb0.01). ⁎Ind
mutants cells (sec18-ts/coq3) were cultured at permissive temperature (25 °C) in YPDwitho
was added and cells were cultured during 4 h at the same conditions. The initial culture was
second at non-permissive temperature (30 °C). Cultures were used to purify mitochondri
Materials and methods and the microsomal fractions were puriﬁed after the centrifugation o
were prepared and Q6 quantiﬁed as described in Materials and methods. Data correspond
representative of a set of two independent experiments.detected in mitochondria or microsomes. After the addition of
exogenous Q6, at permissive temperature (25 °C) the Q6 is readily
transported to mitochondria while at non-permissive temperature
(30 °C) is accumulated mainly in microsomes.
3.4. Q6 uptake by cells requires soluble proteins
Result suggests that exogenous Q6 could utilize the hydrophilic
phase in the lumen of endocytic vesicles to be transported into the
yeast cell. Since Q6 is a hydrophobic molecule, this process would
require the binding to awater soluble factor that would carry this lipid
into the cell. Q6 uptake assays were carried out with cells cultured in a
rich medium containing 2% peptone, an enzymatic digest of animal
protein. The digested proteins seem to be a good candidate to bind
exogenous Q6 to facilitate its transport into the cell. To test this
possibility, a Q6 uptake assay was performed with cells cultured in SD
medium, which does not contain digested proteins as nitrogen source.
Thus, the coq3 null mutant strains CENcoq3 and EG103coq3 and the
double mutant strain coq3/erg2 (Y01812coq3) were cultured until
stationary phase in the presence of 2 μM Q6 with or without 2%
peptone. Cells were collected after 48 h, spheroplasts prepared, and
the content of Q6 determined (Fig. 7). EG103coq3 and CENcoq3 strains
are unable to produce Q6 and also show a moderate amount of Q6
when were cultured with exogenous Q6 in synthetic media. However,
the amount of Q6 was increased after the peptone addition but only in
CENcoq3 strain, that does not show defects on membrane trafﬁc.ted in thermosensitive endocytic mutants at non-permissive temperature. Panel A: Cells
medium at 0.1 OD660nm/ml for 4 h and then exogenous Q6 (2 μM) was added with or
Zymolyase digestion. Lipid extracts of protoplasts were prepared and Q6 quantiﬁed as
inations from the same experiment. Data are representative of a set of two independent
icates that Q6 was not detected in those cells and culture conditions. Panel B: Double
ut the presence of Q6 until reach 2 OD units at 660 nm. At this point exogenous Q6 (2 μM)
split in two cultures; one was cultured 16 h at permissive temperature (25 °C) and the
a (Mito) and microsome (Micro). Mitochondrial fractions were puriﬁed according to
f postmitochondrial supernatant at 100,000 ×g 1 h at 4 °C. Lipid extracts of both samples
to the average±SD of three Q6 determinations from the same experiment. Data are
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Several studies performed inmammalian systems have shown that
certain steps in the Q biosynthetic pathway take place in both
mitochondrial and ER membranes [21,59,60]. Studies in yeast,
however, suggest that Q6 biosynthesis is carried out solely within
mitochondria [30]. Here we show a higher Q6 content in mitochondria
as compared with other cell membranes in wild-type yeast strains
derived from different genetic backgrounds, CEN.PK2-1C and EG103.
Although Q6 content is highest in mitochondria, it is detected in all
yeastmembranes indicating a Q6 transport process frommitochondria
to other cellular membranes. In this study we employed the CENcoq7
null mutant, previously shown to be capable of taking up exogenously
supplied Q6 and respiratory electron transport is restored [50].
Exogenous Q6 uptake by the CENcoq7 null mutant shows a distribu-
tion proﬁle similar in many aspects to its wild-type parent. This
ﬁnding suggests that mitochondrial Q6 uptake in the coq7mutant may
mimic the transport of Q6 from mitochondria to cell membranes in
wild-type strains.
Several authors have indicated that the ER–Golgi system partici-
pates in the coenzyme Q secretion to the blood plasma in mammalian
cells [21]. Other studies suggest that the MAM participates in the
secretory pathway as a component that supplies lipids for the ﬁnal
assembly into very low-density lipoproteins [61]. Thus there is a
precedent for the hypothesis that Q6 transported to ER or MAM from
mitochondria may use the secretory pathway to reach other cell
membranes. Similarly, endocytic vesicles could also transport exo-
genous Q6 to internal cell membranes. Our studies show a low but
signiﬁcant uptake of exogenous Q6 by the EG103coq7 strain, while the
corresponding coq7 mutant in the CEN.PK2-1C background exhibited
nearly wild-type Q6 content in mitochondria and plasma membrane,
and higher than wild-type content of exogenous Q6 in ER and MAM.
Interestingly, the analysis of two well deﬁned phenotypes for
defective membrane trafﬁcking (CPY secretion and anormal vacuolar
morphology) showed that EG103 strains may have a mild defect in
those processes, which suggest that Q6 transport among membranes
is dependent of normal endocytic andmembrane transport within the
cell. Furthermore, the ﬁndings reported here that yeast mutants with
defects in either endocytosis (erg2) or several steps in membrane
trafﬁc (pep12, tlg2 and vps45) fail to transport exogenous Q6 to
mitochondria strongly support this hypothesis. Indeed, not only there
was no delivery of Q6 to mitochondria, but none of the endocytosis
mutants were able to incorporate exogenous Q6 into other cellular
membranes at signiﬁcant levels, including the plasmamembrane. This
last observation is perhaps most surprising, as it indicates that uptake
of exogenously supplied coenzyme Q6 by the plasma membrane
requires an intact endocytosis membrane trafﬁcking system. A time
course analysis of radiolabeled CoQ10 in human cells demonstrated
that it is ﬁrst incorporated in mitochondria and then delivered to
other membranes including plasma membrane [20].
Even though Q6 is a hydrophobic molecule, it is possible that when
it is added exogenously in aqueous media, it is bound to soluble
polypeptides, and taken up by cells via endocytic vesicles. Here we
demonstrated that exogenous Q6 uptake by cells is facilitated by
peptone, indicating that Q6 binding to the soluble proteins and
peptides present in peptone partitions this lipid into the aqueous
phase and allows its incorporation into the lumen of endocytic
vesicles. Mutant strains defective in endocytosis (erg2) fail to take up
exogenous Q6 even with soluble proteins in the medium, supporting
this hypothesis. These data agree with the general scheme of
cholesterol trafﬁcking in mammalian cells [62]. Uptake of CoQ10 by
HL60 cells requires speciﬁcally lipoproteins [20]. Therefore, we
propose a mechanism for uptake, in which exogenous Q6 binds to
soluble proteins, is taken up via endocytosis and travels via endocytic
vesicles to the vacuole, where it must be retrieved in order to be
delivered to the plasma membrane and mitochondria. The Q6 uptakedetected in synthetic media (Fig. 7, Panel A) can represent a non
receptor-mediated endocytic uptake (ﬂuid-phase endocytosis) or a
direct insertion of the Q6 molecule in the plasma membrane. Also, is
possible that the selected mutants do not show a total lack of
endocytosis, a crucial function in the cells, and maintains a minimal
activity that does not support the Q6 uptake to mitochondria.
Receptor-mediated or ﬂuid-phase endocytosis pathways share some
components. In a recent and extensive study has been found 14 genes
in yeast that are related to ﬂuid-phase endocytosis [63]. One of those
genes, TLG2, has been used in this work and probably a tlg2-deleted
mutant strain accumulates defects on both pathways. This interplay
between both processes may also explain the low amount of Q6
detected in endomembranes from double mutants of endocytosis and
Q6 biosynthesis pathway. Each of the membrane trafﬁc mutants used
in this study were unable to take up exogenous Q6 and have defects at
various stages of endocytosis including the initial point of uptake
(erg2), late endosome formation (tlg2, vps45), or vacuole maturation
(pep12).
A point of criticism may be the use of deleted mutants of the
endocytic pathway. However, when was analyzed the Q6 uptake in a
temperature restrictive mutant such as sec18-1/coq3 was found that
at permissive temperature was produced a typical Q6 uptake to
mitochondria. This uptake was blocked at non-permissive conditions.
That allow us discard that the lack of Q6 uptake was produced by the
absence of transport proteins or others factors related with the
mutated genes that could not be expressed in permanent endocytic
mutants. However, this experiment does not demonstrate completely
that endocytic process was required for a proper Q6 uptake. Better, it
demonstrates that at least part of the process, the transport from the
endomembrane system to the mitochondria is supported by the
membrane trafﬁc machinery.
Hence, this model accounts for the absence of signiﬁcant amounts
of exogenous Q6 in the plasma membrane and vacuoles in each of
these mutants. However, it is curious that there is very little
exogenous Q6 detected in vacuoles isolated from either the single
coq7 or coq3 mutants (Figs. 2 and 6, respectively). Perhaps the
relatively high content of Q6 in the vacuole of the wild-type strain
represents the trafﬁcking bottleneck for endogenously synthesized Q6
originating from themitochondria, while the trafﬁcking bottleneck for
Q6 supplied exogenously may reside in the ER or MAM. It is interesting
that other studies of exogenous Q10 uptake by human cells indicate
that the Q10 accumulatesmainly in a vesicular endocytic compartment
[20], and only a small but signiﬁcant amount of Q10 was assimilated by
mitochondria. While the uptake of exogenous Q6 and its delivery to
mitochondria by coq mutant yeast is quite high, uptake into
mitochondria of Q6-replete yeast is quite low [50]. Thus, the amount
of uptake of exogenous Q and its delivery to mitochondria in both
human and yeast cells may reﬂect mechanisms that regulate
mitochondrial Q content. In fact, exogenous Q10 uptake by human
cells induces a decrease of endogenous biosynthesis maintaining Q10
homeostasis [20].
The vesicle trafﬁc system for transport of exogenous Q6 would
allow transport of Q6 to plasma membrane, and also to mitochondria.
The trafﬁcking of Q6, whether synthesized de novo or supplied
exogenously, is likely to share mechanisms in common with higher
eukaryotes. An understanding of the processes involved in yeast
uptake and assimilation of exogenously supplied Q6 will provide
insights into the process by which mammalian cells assimilate Q10.
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